{"prompt": "['Safety of Simultaneous versus Sequential Administration of mRNA COVID-19 Vaccines and', 'Quadrivalent Inactivated Influenza (IIV4) in Adults and Adolescents: A Randomized Observer', 'Blinded Study', 'Short Title: Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Centers for Disease Control & Prevention', 'Clinical Immunization Safety Assessment (CISA) Project', 'Lead Site (Duke University) Principal Investigator: Emmanuel B. Walter, MD, MPH', 'Lead Site Sub-principal Investigator: Ken Schmader, MD', 'Contributing Site (Johns Hopkins University) Principal Investigator: Kawsar Talaat, MD', 'Contributing Site Sub-principal Investigator: Neal Halsey, MD', \"Contributing Site (Cincinnati Children's Hospital Medical Center) Principal Investigator:\", 'Elizabeth Schlaudecker, MD, MPH', 'Contributing Site Sub-principal Investigator: Mary Staat, MD, MPH', 'Centers for Disease Control and Prevention (CDC) Principal Investigator: Karen R. Broder, MD', 'CDC Sub-principal Investigator: Jonathan Duffy, MD, MPH', 'NCT #: NCT05028361', 'Version Number: 2.0', '17 September 2021']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'STATEMENT OF COMPLIANCE', 'This trial will be conducted in compliance with the protocol, the International Conference', 'on Harmonization (ICH) Guideline E6-Good Clinical Practice (GCP), and the applicable', 'guidelines and regulatory requirements from the United States (US) Code of Federal', 'Regulations (CFR), 45 CFR Part 46.', 'All study personnel with subject contact have completed Human Subjects Protection', 'Training.', '2']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'TABLE OF CONTENTS', 'PROTOCOL SUMMARY', '5', '1', 'BACKGROUND', '10', '1.1', 'Background', '10', '1.2', 'Summary and Rationale', '16', '2', 'STUDY OBJECTIVES AND OUTCOME MEASURES', '17', 'Primary', '17', 'Secondary', '18', 'Exploratory', '19', '3', 'STUDY DESIGN', '21', '3.1', 'Main study design', '21', '3.2', 'Laboratory Studies', '22', '4', 'STUDY ENROLLMENT AND WITHDRAWAL', '22', '4.1', 'Subject Inclusion Criteria', '22', '4.2', 'Subject Exclusion Criteria', '23', '4.3', 'Temporary Delay Criteria (Visit 1, 2 and 3 (for primary COVID-19 vaccine series))', '24', '4.4', 'Recruitment', '24', '4.5', 'Reasons for and Handling of Withdrawals', '26', '4.6', 'Termination of Study', '26', '5', 'STUDY SCHEDULE, PROCEDURES, & EVALUATIONS', '26', '5.1', 'Schedule of events and data collection', '26', '5.2', 'Treatment Assignment Procedures', '38', '5.2.1 Randomization', '38', '5.3', 'Data Collection', '39', '5.3.1 Study Product Supply, Storage, and Administration', '39', '5.3.2', 'Blinding', '40', '5.4', 'Reactogenicity and Safety Assessment', '40', '5.4.1 Causality (relatedness) Assessment', '43', '5.4.2', 'Reporting of Adverse Events', '43', '5.4.3', 'Safety Monitoring Plan', '43', '5.5', 'Health-Related Quality of Life (HRQOL)', '43', '5.5.1 Generic Measures of HRQOL', '43', '5.6', 'Biospecimens Collection & Handling', '44', '5.6.1 Serum', '44', '6', 'LABORATORY ANALYSES', '45', '6.1', 'Baseline SARS-CoV-2 antibody', '45', '6.2', 'Influenza Hemagglutination Inhibition (HAI) Assay', '45', '7', 'STATISTICAL CONSIDERATIONS', '46', '7.1', 'Analysis Plan', '46', '3']\n\n###\n\n", "completion": "END"}